Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNA NASDAQ:FBRX NASDAQ:NRIX NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$16.14+1.1%$12.35$5.00▼$16.85$945.42M1.541.64 million shs2.56 million shsFBRXForte Biosciences$15.49+15.3%$11.79$4.11▼$28.68$167.10M3.03104,833 shs65,200 shsNRIXNurix Therapeutics$9.38+3.3%$9.69$8.18▼$29.56$694.16M2.331.16 million shs770,322 shsTERNTerns Pharmaceuticals$8.23+2.5%$6.95$1.87▼$8.46$702.71M-0.031.04 million shs853,673 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks+8.85%+41.48%+44.74%+25.98%+106.65%FBRXForte Biosciences-7.44%-5.68%+21.63%-2.68%+163.27%NRIXNurix Therapeutics-3.40%+9.00%-0.33%-28.67%-58.67%TERNTerns Pharmaceuticals+2.82%+7.93%+6.22%+89.83%-2.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$16.14+1.1%$12.35$5.00▼$16.85$945.42M1.541.64 million shs2.56 million shsFBRXForte Biosciences$15.49+15.3%$11.79$4.11▼$28.68$167.10M3.03104,833 shs65,200 shsNRIXNurix Therapeutics$9.38+3.3%$9.69$8.18▼$29.56$694.16M2.331.16 million shs770,322 shsTERNTerns Pharmaceuticals$8.23+2.5%$6.95$1.87▼$8.46$702.71M-0.031.04 million shs853,673 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks+8.85%+41.48%+44.74%+25.98%+106.65%FBRXForte Biosciences-7.44%-5.68%+21.63%-2.68%+163.27%NRIXNurix Therapeutics-3.40%+9.00%-0.33%-28.67%-58.67%TERNTerns Pharmaceuticals+2.82%+7.93%+6.22%+89.83%-2.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 1.67Reduce$9.00-44.23% DownsideFBRXForte Biosciences 2.50Moderate Buy$68.00338.99% UpsideNRIXNurix Therapeutics 2.76Moderate Buy$29.07209.93% UpsideTERNTerns Pharmaceuticals 2.43Hold$15.4988.19% UpsideCurrent Analyst Ratings BreakdownLatest FBRX, NRIX, DNA, and TERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025DNAGinkgo BioworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NRIXNurix TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TERNTerns PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/17/2025TERNTerns PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$15.009/16/2025TERNTerns PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$15.009/4/2025TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.448/26/2025NRIXNurix TherapeuticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/25/2025DNAGinkgo BioworksBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$6.00 ➝ $9.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.00(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$227.04M4.21N/AN/A$13.17 per share1.23FBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/ANRIXNurix Therapeutics$54.55M13.15N/AN/A$7.44 per share1.26TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$547.03M-$5.86N/AN/AN/A-136.56%-43.25%-22.29%11/11/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.61N/AN/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)Latest FBRX, NRIX, DNA, and TERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/10/2025Q3 2025NRIXNurix Therapeutics-$0.84N/AN/AN/A$16.06 millionN/A8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/7/2025Q2 2025DNAGinkgo Bioworks-$1.44-$1.10+$0.34-$1.10$41.60 million$49.60 million8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/A7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A5.415.41FBRXForte BiosciencesN/A11.7411.74NRIXNurix TherapeuticsN/A6.826.82TERNTerns PharmaceuticalsN/A24.7024.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%FBRXForte Biosciences77.63%NRIXNurix TherapeuticsN/ATERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%FBRXForte Biosciences5.90%NRIXNurix Therapeutics7.40%TERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64059.20 million53.45 millionOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableNRIXNurix Therapeutics30076.45 million70.79 millionOptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableFBRX, NRIX, DNA, and TERN HeadlinesRecent News About These CompaniesTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)October 2 at 4:05 PM | globenewswire.comTerns Pharmaceuticals: Valued As If It Can't WinSeptember 30 at 7:25 AM | seekingalpha.comBrokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $15.49September 25, 2025 | americanbankingnews.comExchange Traded Concepts LLC Grows Stock Position in Terns Pharmaceuticals, Inc. $TERNSeptember 24, 2025 | marketbeat.comGoldman Sachs Group Inc. Has $1.15 Million Stock Position in Terns Pharmaceuticals, Inc. $TERNSeptember 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 22, 2025 | marketbeat.com2 Under-the-Radar Stocks That Could SoarSeptember 21, 2025 | fool.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 5.1% - Here's WhySeptember 20, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Up 10.3% - Should You Buy?September 19, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Upgraded by Barclays to "Strong-Buy" RatingSeptember 19, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Should You Buy?September 18, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Now Covered by BarclaysSeptember 18, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Down 3.5% - Should You Sell?September 14, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Buys New Stake in Terns Pharmaceuticals, Inc. $TERNSeptember 14, 2025 | marketbeat.comDoing good in people’s lives: Amy Burroughs discusses CMLSeptember 11, 2025 | pharmaphorum.comPTerns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comTrexquant Investment LP Cuts Stake in Terns Pharmaceuticals, Inc. $TERNSeptember 10, 2025 | marketbeat.comInvesco Ltd. Raises Holdings in Terns Pharmaceuticals, Inc. $TERNSeptember 10, 2025 | marketbeat.comObesity Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision ...September 9, 2025 | theglobeandmail.comResearch Analysts Issue Forecasts for TERN Q3 EarningsSeptember 9, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. $TERN Shares Purchased by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBRX, NRIX, DNA, and TERN Company DescriptionsGinkgo Bioworks NYSE:DNA$16.14 +0.17 (+1.06%) Closing price 03:59 PM EasternExtended Trading$16.20 +0.07 (+0.41%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Forte Biosciences NASDAQ:FBRX$15.49 +2.05 (+15.25%) Closing price 04:00 PM EasternExtended Trading$15.02 -0.47 (-3.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Nurix Therapeutics NASDAQ:NRIX$9.38 +0.30 (+3.30%) Closing price 04:00 PM EasternExtended Trading$9.37 -0.01 (-0.11%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Terns Pharmaceuticals NASDAQ:TERN$8.23 +0.20 (+2.49%) Closing price 04:00 PM EasternExtended Trading$8.28 +0.05 (+0.61%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
